Evaluation of the Rationality of Hypertension Treatment in Indonesia Based on JNC 7 and JNC 8 Treatment Standards: A Review
DOI:
10.29303/jpm.v21i1.10574Published:
2026-02-09Downloads
Abstract
Hypertension is a multifactorial chronic disease and a leading cause of global morbidity and mortality, with a high prevalence in Indonesia. Irrational pharmacotherapy can reduce therapeutic effectiveness, increase the risk of adverse drug reactions, and exacerbate the economic burden on the healthcare system. This study aims to evaluate the rationality of hypertension treatment in Indonesia based on the Joint National Committee 7 (JNC 7) and 8 (JNC 8) therapy standards. A literature review was conducted on research articles accessed via Google Scholar, published between 2015 and 2025. Of the 675 identified articles, 10 met the inclusion criteria, which required that the articles contain percentage data on the rationality of hypertension treatment and use JNC 7 or JNC 8 as a reference. The results indicate that the appropriate indication aspect achieved the highest level of adherence, with 8 out of 10 studies (80%) reporting 100% compliance. The aspect of appropriate dosage was also high, exceeding 97% in 9 studies (90%). However, the appropriate drug selection rate showed wide variation, ranging from 48.65% to 100%. This inconsistency was primarily attributed to the prevalent use of monotherapy in stage 2 hypertension patients, for whom combination therapy is recommended. Calcium Channel Blockers (CCBs), particularly amlodipine, were the most frequently prescribed antihypertensive class, dominating the prescribing patterns in 8 out of the 10 studies (80%). In conclusion, hypertension treatment in Indonesia demonstrates a high degree of rationality concerning indication, drug selection, and dosage appropriateness, aligning with JNC standards to achieve optimal blood pressure control.
Keywords:
Appropriate Dosage; Appropriate Drug Selection; Hypertension; RationalityReferences
S.-B. Lee, B. Park, K.-W. Hong, and D.-H. Jung, “Genome-wide association of new-onset hypertension according to renin concentration: The Korean Genome and Epidemiology Cohort Study,” J. Cardiovasc. Dev. Dis., vol. 9, no. 4, p. 104, 2022, doi: https://doi.org/10.3390/jcdd9040104.
A. Li et al., “Risk probability and influencing factors of stroke in followed-up hypertension patients,” BMC Cardiovasc. Disord., vol. 22, no. 1, p. 328, Dec. 2022, doi: 10.1186/s12872-022-02780-w.
World Health Organization, “Global report on hypertension: The race against a silent killer,” 2023.
Kementerian Kesehatan Republik Indonesia, “Survei Kesehatan Indonesia (SKI) 2023: Hasil utama – hipertensi berdasarkan diagnosis dokter dan pengukuran tekanan darah,” 2023.
Kementerian Kesehatan Republik Indonesia, “Modul penggunaan obat rasional,” 2011.
World Health Organization, “Promoting rational use of medicines: Core components,” 2002.
S. Aryzki, N. Aisyah, H. Hutami, and B. Wahyusari, “Evaluasi Rasionalitas Pengobatan Hipertensi Di Puskesmas Pelambuan Banjar Masin Tahun 2017,” Jurnal Ilmiah Manuntung, vol. 4, no. 2, pp. 119–128, 2018.
P. K. Whelton et al., “2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines,” Hypertension, vol. 71, no. 6, pp. 1269–1324, Jun. 2018, doi: 10.1161/HYP.0000000000000066.
A. Augustin et al., “Impact of Therapeutic Inertia on Long-Term Blood Pressure Control,” Hypertension, vol. 77, no. 4, pp. 1350–1359, Apr. 2021, doi: 10.1161/HYPERTENSIONAHA.120.15866.
N. Herawati, G. A. R. Saputri, and A. S. Yasir, “Evaluasi Rasionalitas Penggunaan Antihipertensi pada Pasien Geriatri di RSUD Dr. H Bob Bazar, SKM Lampung Selatan,” Journal of Islamic Medicine, vol. 5, no. 2, pp. 133–140, Sep. 2021, doi: 10.18860/jim.v5i2.13435.
H. Hamzah, S. Sapril, and I. Irmayana, “Profil Peresepan Obat Hipertensi pada Pasien Rawat Jalan di Puskesmas Betoambari Periode Januari – Juni Tahun 2020 Di Kota Baubau,” Jurnal Sains dan Kesehatan, vol. 1, no. 1, pp. 6–10, May 2022, doi: 10.57151/jsika.v1i1.15.
T. Milman, R. A. Joundi, N. M. Alotaibi, and G. Saposnik, “Clinical inertia in the pharmacological management of hypertension,” Medicine, vol. 97, no. 25, p. e11121, Jun. 2018, doi: 10.1097/MD.0000000000011121.
T. Unger et al., “2020 International Society of Hypertension Global Hypertension Practice Guidelines,” Hypertension, vol. 75, no. 6, pp. 1334–1357, Jun. 2020, doi: 10.1161/HYPERTENSIONAHA.120.15026.
G. Mukti, S. B. Harsono, and L. M. Cahyo, “Analisis Rasionalitas Penggunaan Obat Antihipertensi Pada Pasien Geriatri di Rumah Sakit X Periode Tahun 2023,” Jurnal Mandala Pharmacon Indonesia, vol. 10, no. 2, pp. 389–396, Dec. 2024, doi: 10.35311/jmpi.v10i2.558.
M. A. Yuswar, N. U. Purwanti, and U. Khairiyah, “Gambaran Rasionalitas Penggunaan Obat Antihipertensi pada Pasien Hipertensi di Instalasi Rawat Jalan RSUD Sultan Syarif Mohamad Alkadrie Pontianak Tahun 2020,” Jurnal Pharmascience, vol. 10, no. 1, pp. 120–131, Feb. 2023, doi: 10.20527/jps.v10i1.14041.
M. F. Fatkhiya and D. A. Ningrum, “Analisis Rasionalitas Penggunaan Obat pada Pasien Hipertensi Rawat Jalan di RSUD Bendan,” Jurnal Pharmascience, vol. 11, no. 2, pp. 327–336, Oct. 2024, doi: 10.20527/jps.v11i2.17203.
F. Hermanto, A. Choirunissa, T. H. Sutarna, R. Amelia, and A. Rizwan, “Evaluation of The Rationality of Hypertension Medication Use in Puskesmas Central Cimahi,” Jurnal Penelitian Pendidikan IPA, vol. 10, no. 9, pp. 6977–6983, Sep. 2024, doi: 10.29303/jppipa.v10i9.8673.
E. K. Untari, A. R. Agilina, and R. Susanti, “Evaluasi rasionalitas penggunaan obat antihipertensi di Puskesmas Siantan Hilir Kota Pontianak tahun 2015,” Pharmaceutical Sciences and Research, vol. 5, no. 1, pp. 32–39, 2018, doi: https://doi.org/10.7454/psr.v5i1.3870.
A. Diwati and O. Sofyan, “Profil dan Rasionalitas Penggunaan Obat Antihipertensi Pada Pasien Hipertensi Di Fasilitas Kesehatan Tingkat Pertama Periode Mei - Juli 2021,” Majalah Farmaseutik, vol. 19, no. 1, pp. 1–8, Mar. 2023, doi: 10.22146/farmaseutik.v19i1.80153.
M. Yusuf, S. Widodo, and D. Pitaloka, “Rasionalitas Penggunaan Obat Antihipertensi Pada Pasien Hipertensi Rawat Inap di RS Daerah Dr. A. Dadi Tjokrodipo Bandar Lampung,” JFL : Jurnal Farmasi Lampung, vol. 9, no. 1, pp. 27–31, Jun. 2020, doi: 10.37090/jfl.v9i1.329.
M. Khaer and O. Tjandra, “Pola penggunaan obat antihipertensi pada lansia di Puskesmas Kecamatan Pulo Gadung periode Juli-Desember 2020,” Tarumanagara Medical Journal, vol. 4, no. 1, pp. 141–147, Apr. 2022, doi: 10.24912/tmj.v4i2.16396.
C. I. Pratiwi, A. M. Ulfa, and S. Wijaya, “Rasionalitas Penggunaan Obat Hipertensi Pada Pasien BPJS Di Puskesmas Rantau Tijang Tanggamus,” Jurnal Medika Malahayati, vol. 7, no. 1, pp. 562–572, Apr. 2023, doi: 10.33024/jmm.v7i1.9499.
P. A. James et al., “2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults,” JAMA, vol. 311, no. 5, pp. 507–520, Feb. 2014, doi: 10.1001/jama.2013.284427.
K. G. Bulsara, P. Patel, and M. Cassagnol, “Amlodipine,” in StatPearls, StatPearls Publishing, 2024.
F. Marte, P. Sankar, P. Patel, and M. Cassagnol, “Captopril,” in StatPearls, StatPearls Publishing, 2024.
P. Rodriguez, V. T. San Martin, and K. M. Pantalone, “Therapeutic Inertia in the Management of Type 2 Diabetes: A Narrative Review,” Diabetes Therapy, vol. 15, no. 3, pp. 567–583, Mar. 2024, doi: 10.1007/s13300-024-01530-9.
S. W. Winda, “Formularium Nasional (FORNAS) dan e-Catalogue Obat Sebagai Upaya Pencegahan Korupsi dalam Tata Kelola Obat Jaminan Kesehatan Nasional (JKN),” Integritas : Jurnal Antikorupsi, vol. 4, no. 2, pp. 30–41, Dec. 2018, doi: 10.32697/integritas.v4i2.328.
Wahyu Apriliany, Ganet Eko Pramukantoro, and T. Wijayanti, “Analisis Penggunaan Obat Antihipertensi pada Pasien Program Rujuk Balik (PRB) di Apotek Kabupaten ‘A’ Dengan Metode ATC/DDD dan DU 90%,” Jurnal Farmasi Komunitas, vol. 10, no. 1, pp. 97–103, May 2023, doi: 10.20473/jfk.v10i1.38159.
M. Mygel, A. B. Septianingsih, and R. Anindita, “Acceptance of Implementation of Drug Management and Its’ Barriers on Hospital Management Information Systems,” International Journal of Nursing and Health Services (IJNHS), vol. 7, no. 5, pp. 141–147, Oct. 2024, doi: 10.35654/ijnhs.v7i5.797.
D. H. Ali et al., “Therapeutic inertia in the management of hypertension in primary care,” J. Hypertens., vol. 39, no. 6, pp. 1238–1245, Jun. 2021, doi: 10.1097/HJH.0000000000002783.
Y. L. Niriayo, S. Girmay, N. Tesfay, K. Gidey, and S. W. Asgedom, “Therapeutic inertia and contributing factors among ambulatory patients with hypertension,” BMC Cardiovasc. Disord., vol. 24, no. 1, p. 523, Sep. 2024, doi: 10.1186/s12872-024-04109-1.
Y. Anggriani, H. U. Ramadaniati, P. Sarnianto, J. Pontoan, and S. Suryawati, “The Impact of Pharmaceutical Policies on Medicine Procurement Pricing in Indonesia Under the Implementation of Indonesia’s Social Health Insurance System,” Value Health Reg. Issues, vol. 21, pp. 1–8, May 2020, doi: 10.1016/j.vhri.2019.05.005.
Dinda Juliana and Dika Pramita Destiani, “Pola Peresepan Obat Antihipertensi pada Pasien BPJS Kesehatan dibeberapa Apotek Daerah Bandung Periode November 2023,” OBAT: Jurnal Riset Ilmu Farmasi dan Kesehatan, vol. 2, no. 5, pp. 30–39, Aug. 2024, doi: 10.61132/obat.v2i5.612.
Y. Lu, O. Arowojolu, X. Qiu, Y. Liu, L. A. Curry, and H. M. Krumholz, “Barriers to Optimal Clinician Guideline Adherence in Management of Markedly Elevated Blood Pressure,” JAMA Netw. Open, vol. 7, no. 8, p. e2426135, Aug. 2024, doi: 10.1001/jamanetworkopen.2024.26135.
L. A. Setiani, O. Z. Toha, E. M. Fauzi, and B. Burmanajaya, “Hubungan Rasionalitas Penggunaan Obat Antihipertensi terhadap Outcome Klinis Pasien Krisis Hipertensi di RSUD Kota Bogor,” Indonesian Journal of Clinical Pharmacy, vol. 14, no. 1, pp. 12–28, May 2025, doi: 10.15416/ijcp.2025.v14i1.58844.
M. L. Fahrni, M. T. Azmy, E. Usir, N. A. Aziz, and Y. Hassan, “Inappropriate prescribing defined by STOPP and START criteria and its association with adverse drug events among hospitalized older patients: A multicentre, prospective study,” PLoS One, vol. 14, no. 7, p. e0219898, Jul. 2019, doi: 10.1371/journal.pone.0219898.
N. Rahmi Hidayati, V. Salsabila Kumaedi, R. Susilo, L. Sulastri Sekolah Tinggi Farmasi Muhammadiyah Cirebon, and J. Cideng, “Rasionalitas Penggunaan Obat Anti Hipertensi pada Pasien Hipertensi di Instalasi Rawat Inap RSD XXX Cirebon,” 2022.
E. A. Adistia, I. Rahmania, E. Dini, and E. Annisaa’, “Hubungan antara Rasionalitas Penggunaan Antihipertensi terhadap Keberhasilan Terapi Pasien Hipertensi di RSND Semarang,” Generics : Journal of Research in Pharmacy Accepted : 5 Mei, vol. 2, no. 1, 2022.
D. Andriani, L. O. Ali Hanafi, and J. Pusmarani, “Evaluasi Rasionalitas Penggunaan Obat Hipertensi di Puskesmas Langara Konawe Kepulauan Sulawesi Tenggara Tahun 2020,” Jurnal Pharmacia Mandala Waluya, vol. 2, no. 2, pp. 76–85, Apr. 2023, doi: 10.54883/28296850.v2i2.64.
D. Darwis, Y. Rikmasari, and W. N. Santi, “Rasionalitas Penggunaan Obat dan Kepatuhan Pasien Hipertensi di Puskesmas Mekarsari dan Puskesmas Lebubg Bandung Kabupaten Ogan Ilir pada Bulan Mei-Juli 2016,” Jurnal Ilmiah Bakti Farmasi, vol. 3, no. 2, 2018.
T. Hardiyanti, S. Wahab, H. Muliana, and E. Sepriana, “Evaluasi Rasionalitas Penggunaan Obat Antihipertensi Pada Pasien Hipertensi Rawat Jalan Di Rumah Sakit Pusri Palembang Periode Oktober 2019 - Maret 2020,” Journal of Health Science, vol. 2, no. 2, pp. 31–38, Aug. 2024, doi: 10.54816/jhs.v2i2.542.
A. F. Rahman Abdillah, L. D. Buton, and R. U. Kasih, “Analisis Rasionalitas Penggunaan Obat Anti Hipertensi Pasien Rawat Jalan Di Puskesmas Atari Jaya Kecamatan Lalembuu Kabupaten Konawe Selatan,” Jurnal Pharmacia Mandala Waluya, vol. 1, no. 2, pp. 46–53, Apr. 2022, doi: 10.54883/jpmw.v1i2.11.
M. A. Pinem, I. Oktadiana, E. Sugesti, and A. Siregar, “Evaluasi Rasionalitas Penggunaan Obat pada Pasien Hipertensi Rawat Jalan di RSUD Perdagangan Tahun 2024,” Duta Pharma Journal, vol. 4, no. 2, 2024.
D. A. Mpila and W. A. Lolo, “Correlation Between Rationality of Antihypertensive Drugs Use and Clinical Outcomes in Hypertensive Patients at Manado Imanuel Clinic,” PHARMACON, vol. 11, no. 1, 2022.
K. K. Shetty, R. K. Shetty, N. C. S. Ganiga, R. P. Reddy, and V. Nayak, “Calcium channel blockers induced pedal oedema; mechanism and treatment options: Review,” Int. J. Sci. Appl. Res., vol. 2, no. 12, pp. 27–33, 2015.
A. C. Puspitasari, Ovikariani, and G. R. Al Farizi, “Evaluasi Penggunaan Obat Antihipertensi pada Pasien Hipertensi Geriatri di Klinik Pratama Annisa Semarang,” Jurnal Surya Medika (JSM), vol. 8, no. 1, 2022.
P. Setia Winanti, D. Arisandi, S. S. Wulan Sari Program Studi, and F. Klinik dan Komunitas Sekolah Tinggi Ilmu Kesehatan Bina Cipta Husada Purwokerto, “Evaluasi Rasionalitas Penggunaan Obat Antihipertensi Pada Pasien Hipertensi Di Instalasi Rawat Jalan RSUD Dr. R. Goeteng Taroenadibrata Periode Agustus 2023,” 2024.
A. Quraisy Aljufri et al., “Hubungan Antara Rasionalitas dengan Efektivitas Antihipertensi pada Pasien Hipertensi Dewasa di RSUP Dr. R. Soetijono Blora Rationality and Effectiveness of Antihypertensive Therapy in Adult Hypertension Patients at Dr. R. Soetijono Blora Hospital,” Social Clinical Pharmacy Indonesia Journal, vol. 10, 2025.
A. G. F. Momuat and E. Annisaa, “Rationality Evaluation of Angiotensin II Receptor Blocker (ARB) as Antihypertensive Drug in Chronic Kidney Disease Patients,” Generics : Journal of Research in Pharmacy, vol. 3, no. 1, 2023.
F. Pratama, N. Feladita, and A. Primadiamanti, “Evaluasi Penggunaan Obat Antihipertensi pada Pasien Hipertensi Rawat Jalan di Puskesmas Rawajitu,” Jurnal Farmasi Malahayati, no. 1, 2023.
R. Alnadia, N. U. Purwanti, and R. Susanti, “Evaluasi rasionalitas dan efek samping obat antihipertensi di Puskesmas Singkawang Utara II periode Januari-Juni tahun 2019,” Jurnal Kesehatan Khatulistiwa, vol. 8, no. 2, pp. 24–30, 2022, doi: 10.26418/jurkeswa.v8i2.
A. M. Ulfa, M. P. Angin, and F. N. Azizah, “Rasionalitas Penggunan Obat Antidiabetes Melitus Tipe II Komplikasi Hipertensi pada Pasien Rawat Inap di Rumah Sakit Pertamina Bintang Amin Tahun 2020,” Jurnal Ilmu Kedokteran dan Kesehatan, vol. 9, no. 3, 2022.
License
Copyright (c) 2026 Pratama Immanuel Parlinggoman Sagala, Atika Atika, Jef Gishard Kristo Kalalo
This work is licensed under a Creative Commons Attribution 4.0 International License.
The following terms apply to authors who publish in this journal:
1. Authors retain copyright and grant the journal first publication rights, with the work simultaneously licensed under a Creative Commons Attribution License 4.0 International License (CC-BY License) that allows others to share the work with an acknowledgment of the work's authorship and first publication in this journal.
2. Authors may enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., posting it to an institutional repository or publishing it in a book), acknowledging its initial publication in this journal.
3. Before and during the submission process, authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website), as this can lead to productive exchanges as well as earlier and greater citation of published work (See The Effect of Open Access).
Downloads
How to Cite
